Sensitivity and positive predictive value of CT, MRI and I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study

Nuclear Medicine Communications

Volumn 27, Issue 7, 2006, Pages 583-587

  Lumachi, Franco ^a   Tregnaghi, Alberto ^b   Zucchetta, Pietro ^c   Cristina Marzola, Maria ^c   Cecchin, Diego ^c   Grassetto, Gaia ^c   Bui, Franco ^c  

^a Department of Surgical Sciences   (Italy)

^b Radiology Department   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Arterial hypertension; CT; MIBG scintigraphy; MRI; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; PENTETATE TECHNETIUM TC 99M;

ADOLESCENT; ADRENALECTOMY; ADULT; AGED; ARTICLE; CANCER SURGERY; CHEMODECTOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NECROSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PROSPECTIVE STUDY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748114926     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200607000-00006     Document Type: Article

References (25)

1. Bentrem DJ, Pappas SG, Ahuja Y, Murayama KM, Angelos P. Contemporary surgical management of pheochromocytoma. Am J Surg 2002; 184:621-625.
2. Goldfien A. Adrenal medulla. In: Greenspan FS, Gardner DG (editors): Basic & Clinical Endocrinology. New York: Lange Medical Books/McGraw-Hill; 2001, pp. 399-421.
3. Goldstein RE, O'Neill Jr JA, Holcomb 3rd GW, Morgan 3rd WM, Neblett 3rd WW, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229:755-766.
4. Havlik RJ, Cahow, Kinder BK. Advances in the diagnosis and treatment of pheochromocytoma. Arch Surg 1988; 123:626-630.
5. Wittels RM, Kaplan EL, Roizen MF. Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice. Arch Intern Med 2000; 160:2521-2524.
6. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Familial Cancer 2005; 4:61-68.
7. Sheps SG, Jiang NS, Klee GG. Diagnostic evaluation of pheochromocytoma. Endocrinol Metab Clin North Am 1998; 17:397-414.
8. Lenz T, Ross A, Schumm-Draeger P, Schulte KL, Geiger H. Clonidine suppression test revisited. Blood Press 1998; 7:153-159.
9. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315-329.
10. Berglund AS, Hulthen UL, Manhem P, Thorsson O, Wollmer P, Törnquist C. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of pheochromocytomas. J Intern Med 2001; 249:247-251.
11. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol 2003; 29:483-490.
12. Pacak K, Eisenhofer G, Carrasuillo JA, Chen CC, Whatley M, Goldstein DS. Diagnostic localization of pheochromocytoma. The coming of age of positron emission tomography. Ann NY Acad Sci 2002; 970:170-176.
13. Manger WM, Gifford Jr RW. Pheochromocytoma: current diagnosis and management. Cleveland Clin J Med 1993; 60:365-378.
14. 131I norcholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours. Nucl Med Commun 2002; 23:951-969.
15. Maurea S, Lastoria S, Cuocolo A, Celentano L, Salvatore M. The diagnosis of non-functioning pheochromocytoma. The role of I-123 MIBG imaging. Clin Nucl Med 1995; 20:22-24.
16. Solanski KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the distribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13:513-521.
17. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43:217-223.
18. O'Doherty MJ, MacDonald EA, Barrington SF, Mikhael NG, Schey S. Positron emission tomography in the management of lymphomas. Clin Oncol 2002; 14:415-426.
19. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med 2002; 32:240-271.
20. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:8362-8370.
21. Bergström M, Eriksson B, Oberg K, Sundin A, Ahlstrom H, Linder KJ, et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 1996; 37:32-37.
22. 18F DOPA whole-body PET. Initial results. Radiology 2002; 22:507-512.
23. 18F] Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6-8.
24. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34:173-179.
25. Van Gils AP, van Erkel AR, Falke TH, Pauwels EK. Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities. Eur J Nucl Med 1994; 21: 239-253.